NCT06066840View on ClinicalTrials.gov

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

PHASE4RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Safety and Efficacy
Interventions
DRUG

Basiliximab

Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.

DRUG

Vedolizumab

Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

Affiliated Hospital of Nantong University

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT06066840 - Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement | Biotech Hunter | Biotech Hunter